KRAKOW, Poland, March 27, 2025 /PRNewswire/ — Selvita S.A. (WSE: SLV), one of Europe’s leading preclinical CROs, has announced its financial results for 2024 and provided an update on its backlog for 2025. Key Highlights: In Q4 2024, Selvita generated EUR 22.5 million in commercial…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.